Moderna shares surged 176% after its personalised mRNA cancer vaccine, developed with Merck, delivered positive interim Phase 3 melanoma results! AI caught the rally!

 Moderna Doubles!

Moderna shares surged 176% after its personalised mRNA cancer vaccine, developed with Merck, delivered positive interim Phase 3 melanoma results. Combined with Keytruda, the treatment met both primary endpoints by reducing recurrence. This is the biggest single-day biotech move of 2026 and the most significant cancer trial result since the mRNA and reviving confidence in mRNA technology globally.

The Fulgent AI engine that site on the MetaStock platform caught the big money move just in time as the Swing Trade AI engine returned more than 191% since the buy signal in July!

Winning with AI:

More information on the Fulgent AI engine follow this link: https://www.metastock.com/offer/addon?whc=alphaharvestf